Recently, upregulation of PKM2 was reported in erlotinib-resistant lung cancer cells; mechanistically, this might be due to a decrease in long non-coding (lnc) RNA H19-mediated, ubiquitin-induced PKM2 degradation, such that PKM2 confers resistance to erlotinib through phosphorylation of AKT [16]. This evidence concerns the gene H19 and lung carcinoma.